"description","instanceType","id","name","uuid:ID","text","label"
"Main objective","Objective","Objective_1","OBJ1","500ce1d7-8ac2-4969-b8a2-d883a7c5c864","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).",""
"Safety","Objective","Objective_2","OBJ2","9df1e6a5-b9fd-4bbd-acf2-874c0ed12933","To document the safety profile of the xanomeline TTS.",""
"Behaviour","Objective","Objective_3","OBJ3","88ff9560-8653-4cff-9795-3801f29506ad","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.",""
"","Objective","Objective_4","OBJ4","45e9a2d0-3513-43bf-b04b-7cffd384f343","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).",""
"","Objective","Objective_5","OBJ5","1926ae2b-0b18-43f9-8e7f-66d79c8fa859","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).",""
"","Objective","Objective_6","OBJ6","136cd134-6a0b-47f8-9f10-154a441fee07","To assess the treatment response as a function of Apo E genotype.",""
